Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02289898
terminatedphase_1

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

NCT01952249
completedphase_1

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

NCT01189929
completedphase_1

A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer

NCT01189968
completedphase_2

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

NCT02259582
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02289898Phase 2

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Completed
NCT01952249Phase 1

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Terminated
NCT01189929Phase 1

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Completed
NCT01189968Phase 1

A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Completed
NCT02259582Phase 2

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Completed
NCT02722954Phase 1

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6